Long-term outcomes following CAR T cell therapy: what we know so far
Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …
[PDF][PDF] Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the …
OP-EHEA191011_online 2313..2340 Page 1 Low-density lipoproteins cause atherosclerotic
cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus …
cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus …
Paradigms on immunotherapy combinations with chemotherapy
Checkpoint inhibitors are being added to standard-of-care chemotherapy in multiple clinical
trials. Success has been reported in non–small and small cell lung carcinomas and …
trials. Success has been reported in non–small and small cell lung carcinomas and …
Enhancing anti-tumour efficacy with immunotherapy combinations
Several tumour types are responsive to immunotherapy, as shown by regulatory approvals
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
CD4+ T cell help is required for the formation of a cytolytic CD8+ T cell subset that protects against chronic infection and cancer
Although CD4+ T cell" help" is crucial to sustain antiviral immunity, the mechanisms by
which CD4+ T cells regulate CD8+ T cell differentiation during chronic infection remain …
which CD4+ T cells regulate CD8+ T cell differentiation during chronic infection remain …
Clinical lessons learned from the first leg of the CAR T cell journey
Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies has surpassed
expectations, driving an ever-expanding number of clinical trials and the first US Food and …
expectations, driving an ever-expanding number of clinical trials and the first US Food and …
Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management
Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment for hematologic
malignancies. Two CAR T-cell products are now approved for clinical use by the US FDA …
malignancies. Two CAR T-cell products are now approved for clinical use by the US FDA …
CAR T cell therapies for patients with multiple myeloma
Despite several therapeutic advances over the past decade, multiple myeloma (MM)
remains largely incurable, indicating a need for new treatment approaches. Chimeric …
remains largely incurable, indicating a need for new treatment approaches. Chimeric …
CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive …
The immunosuppressive tumor microenvironment (TME) represents a major barrier for
effective immunotherapy. Tumor-associated macrophages (TAMs) are highly heterogeneous …
effective immunotherapy. Tumor-associated macrophages (TAMs) are highly heterogeneous …
Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma
Glioblastoma multiforme (GBM) is the most common and aggressive form of primary brain
cancer, for which effective therapies are urgently needed. Chimeric antigen receptor (CAR) …
cancer, for which effective therapies are urgently needed. Chimeric antigen receptor (CAR) …